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New molecular biologic techniques, particularly representational difference analysis,
consensus sequence–based polymerase chain reaction, and complementary DNA library
screening, have led to the identification of several previously unculturable infectious agents.
New agents have been found in tissues from patients with Kaposi’s sarcoma, non-A, non-
B hepatitis, hantavirus pulmonary syndrome, bacillary angiomatosis, and  Whipple’s disease
by using these techniques without direct culture. The new methods rely on identifying
subgenomic fragments from the suspected agent. After a unique nucleic acid fragment
belonging to an agent is isolated from diseased tissues, the fragment can be sequenced and
used as a probe to identify additional infected tissues or obtain extended portions of the
agent’s genome. For agents that cannot be cultured by standard techniques, these
approaches have proved invaluable for identification and characterization studies. Applying
these techniques to other human diseases of suspected infectious etiology may rapidly
elucidate novel candidate pathogens.
Identifying the causative agent of an infectious
disease is the cornerstone for its eventual control.
In recent years, a great deal of progress has been
made in identifying new agents associated with both
well-known and newly emerging infectious diseases.
A number of syndromes exist, however, in which
infectious etiology is likely, but the pathogen resists
cultivation with standard microbiologic techniques.
For emerging diseases, rapid identification and char-
acterization of the responsible agent are crucial first
steps for epidemic control.
The rapid identification of a hantavirus respon-
sible for an outbreak of severe pulmonary distress
syndrome in the southwestern United States (1, 2)
demonstrated that applying molecular biologic ap-
proaches can accelerate the identification of an
unknown agent. With extensive nucleic acid and
protein databases readily available, isolating and
sequencing genomic fragments from an unknown
agent can provide important clues regarding its ori-
gin and biologic behavior. Once a new agent’s
phylogenetic relationship to other known organisms
is established, appropriate culture conditions, sero-
logic tests, and perhaps even therapeutic strategies
can be rapidly developed.
Although they have revolutionized our ability to
identify new pathogens, innovative molecular bio-
logic techniques must be applied in conjunction with
traditional epidemiologic procedures. Beral, Jaffe and
colleagues, for example, showed that AIDS-related
Kaposi’s sarcoma (KS) is likely to be caused by a
transmissible agent other than human immunodefi-
ciency virus (HIV), before any likely causative agent
was isolated (3, 4). These findings focused the atten-
tion of investigators on AIDS-KS, which resulted in
the isolation of viral DNA from AIDS-KS lesions and
the description of a new human herpesvirus (5, 6).
Spurious associations between infectious agents and
diseases are common, however, and only through
careful epidemiologic studies can a causal link be-
tween an organism and a disease be established.
Epidemiologic criteria for causality (7-9), supersed-
ing Koch’s postulates, have been used for 30 years,
and a critical phase in the process of new pathogen
discovery involves the unambiguous establishment
that an agent is central to the disease process.
The various molecular biologic approaches to
agent identification differ in technical detail, but all
rely on isolating nucleic acid fragments belonging to
the agent’s genome from diseased tissue. The for-
midable tasks of identifying and separating small
unique nucleic acid fragments from human genomic
material have been approached by various means,
each with its own particular strengths and weak-Emerging Infectious Diseases Vol. 2, No. 3—July-September 1996
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Figure. Schematic representation of different molecular approaches to the identification of unculturable
infectious agents.
nesses. The appropriate technique depends on the
type of infectious agent involved (e.g., bacterial or
viral), whether the disease occurs in a normally ster-
ile site, and whether it can be passaged through
animals.
Once a fragment from the agent’s genome is iso-
lated and sequenced, standard genomic walking
techniques are used to extend the known sequence,
and computer homology searches can be used to
identify the likely phylogenetic relationship of the
agent to other known organisms. In this  article, we
highlight recent successful situations when  molecu-
lar approaches were used to identify and characterize
unknown agents of infectious diseases.
Representational Difference Analysis
Representational difference analysis is one of the
more robust methods of identifying new agents since
it does not require prior knowledge of the agent’s
class (10). The technique is based on polymerase
chain reaction (PCR) enrichment of DNA fragments
present in diseased tissue but absent from healthy
tissues of the same patient (Figure). Representa-
tional difference analysis is also an important tool
for identifying polymorphic DNA sequences associ-
ated with noninfectious diseases (11).
Representational difference analysis depends
first on digesting DNA from both healthy and dis-
eased tissues by using a restriction enzyme and then
on separately “simplifying” the resulting genomes
to reduce their sequence complexity. This is done by
ligating PCR primers to both sets of DNA and
nonspecifically amplifying the mixtures. Since PCR
most efficiently amplifies fragments of 150 to1500
bp, restriction fragments in this size range are en-
riched, and the fragments of the sequence
represented outside this size range (90%) are re-
duced.
Unique strands of DNA from diseased tissue rep-
resenting restriction fragments of an exogenous
agent are isolated in a subtractive hybridization pro-
cess coupled to PCR amplification. First, the
priming sequences ligated on DNA restriction frag-
ments of both normal and infected tissues are
removed. New primer sequences are ligated only
to the diseased tissue DNA fragments. These are
then hybridized with an excess of the healthy tis-Vol. 2, No. 3—July-September 1996 Emerging Infectious Diseases
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sue representation. Human DNA fragments com-
mon to both diseased and healthy tissues reanneal
to each other and, since the healthy tissue frag-
ments are in excess, any given human fragment
derived from the diseased tissue will reanneal to
a complementary strand from the healthy tissue
representation. Thus, common human sequences
found in both representations will only have one
PCR priming sequence or none present on two
complementary strands. However, DNA fragments
from the infectious agent will not find complemen-
tary strands in the healthy tissue representation
and will reanneal with each other. Only hybrids
with both strands derived from the diseased tis-
sue representation will have priming sites and be
able to undergo subsequent exponential PCR am-
plification. Several rounds of representational
difference analysis are performed, which succes-
sively enrich the mixture for unique DNA
sequences present only in the diseased tissue rep-
resentation.
KS-Associated Herpesvirus and KS
The power of representational difference analy-
sis and the difficulties encountered in establishing
the etiology of disease are illustrated by its applica-
tion to KS (5), a vascular neoplasm that frequently
occurrs in homosexual men with AIDS (3). Geo-
graphic clustering (12, 13) and association with
specific sexual behavior (4, 14) suggest that the dis-
ease is caused by a sexually transmitted agent.
Several agents have been investigated, including
human cytomegalovirus (CMV), human papil-
lomavirus, human herpesvirus 6 (HHV-6), and HIV
(for review, see [15]), but no convincing etiologic link
has been established.
Using representational difference analysis,
Chang and colleagues isolated two unique DNA se-
quences (KS330Bam and KS631Bam) from a KS
lesion in an AIDS patient (5). These DNA sequences
are homologous to portions of minor capsid and tegu-
ment protein genes from Epstein-Barr virus (EBV)
and herpesvirus saimiri (HVS), a New World mon-
key herpesvirus. Both EBV and HVS are gamma
herpesviruses associated with neoplastic disorders
in humans (EBV) (16) and nonhuman primates (HVS)
(17). These results suggested that a new human her-
pesvirus, now called KS-associated herpesvirus
(KSHV or HHV-8), could be the KS agent.
The strong association between KS and KSHV
was demonstrated by using Southern hybridization
and PCR to amplify a 233-bp DNA fragment (KS330233)
internal to KS330Bam from all 25 intact and
amplifiable DNA samples from KS lesions that were
examined (5). Ninety tissues from patients without
AIDS or KS were examined, and none showed evi-
dence of KSHV infection.
Although controversy remains over the role of
KSHV in KS (18-20), epidemiologic and biologic stud-
ies strongly suggest that the agent is a causal factor
in KS (21). KSHV has now been identified in 211
(94.2%) of 224 KS lesions examined by a number of
groups around the world, and the virus is found in
all forms of KS, AIDS-related and non-AIDS-related
(22-29). Two independent studies have shown that
KSHV is present in peripheral blood mononuclear
cells  of AIDS-KS patients before onset of KS (30,
31), indicating that the virus is unlikely to be a “pas-
senger virus” in KS lesions. Further, the virus has
been localized to KS tumor tissues by
semiquantitative PCR (25) and by PCR in-situ hy-
bridization (26). The virus has only been found in 8
(1.8%) of 449 solid tissues from control patients with-
out KS (5, 22, 25, 27, 28, 32, 38) and thus appears to
be specifically associated with KS. Although early
reports suggested that the virus is present in skin
tumors from transplant patients without KS (19),
subsequent studies have not confirmed this finding
(33, 34). One study has found evidence of viral DNA
by nested PCR, but not unnested PCR, in semen
from (23%) of healthy donors; these results suggest
that the prevalence of infection in North America
may be higher than that indicated by tissue or lym-
phocyte studies (35). This intriguing finding has not
been reproduced by other groups (23, 36); however,
it should be explored in large rigorous studies.
Lymphoproliferative disorders are common sec-
ondary malignancies in KS patients with and
without AIDS (37). KSHV has also been found in a
rare subset of AIDS-related, body cavity-based
lymphomas, which are manifested as primary ef-
fusions (5, 38). In these AIDS-related lymphomas,
tumor cells are coinfected with EBV (38, 39) but,
unlike tumor cells in EBV-related Burkitt’s
lymphomas, these cells do not exhibit c-myc gene
rearrangement. EBV-uninfected, KSHV-related
body cavity-based lymphomas have also recently
been identified (40, 43). Another
lymphoproliferative syndrome associated with KS
is Castleman’s disease in both AIDS patients and
HIV-seronegative patients. KSHV has been found
in AIDS-related multicentric Castleman’s disease
lesions at a high copy number and less frequently
in tissues from Castleman’s disease patients with-
out AIDS (41).
Identifying KSHV DNA sequences by repre-
sentational difference analysis also led to the quick
identification of an in vitro culture system for grow-
ing the virus. KS330Bam and KS631Bam probes were
used to identify a B-cell line derived from a bodyEmerging Infectious Diseases Vol. 2, No. 3—July-September 1996
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cavity-based lymphoma that was stably infected
with both KSHV and EBV (42). Extended sequenc-
ing and transmission studies have been performed
with body cavity-base lymphoma cell lines, which
clearly define KSHV as a new human herpesvirus
of the genus Rhadinovirus (6). This has recently
been confirmed by detecting herpesvirus particles
in a body cavity-based lymphoma cell line by elec-
tron microscopy (43).
Discovery of a continuously infected cell line
has allowed the first generation of serologic as-
says for KSHV antibodies to be developed (6).
Second-generation immunoblotting assays, which
appear to be both sensitive and specific for de-
tecting KSHV antibodies, indicate that KS patients
are infected with the virus months to years be-
fore the disease develops and that few North
American blood donors are infected (S-J Gao, P.S.
Moore, unpublished observation). Thus, identify-
ing a virus associated with KS by using molecular
approaches has rapidly led to new assays that use
traditional serologic techniques for detecting in-
fection.
HHV-6 and Multiple Sclerosis
The difficulties of using representational dif-
ference analysis for new pathogen identification
 are also illustrated by the search for the agent
that causes multiple sclerosis (MS) (44). An infec-
tious cause for MS has been proposed (45-47), and
geographic and household clustering of cases con-
sistent with an infectious process have been shown
(45, 48-50). Challoner and colleagues used DNA
from sclerotic plaques in brain tissues from MS
patients and performed representational differ-
ence analysis against pooled DNA from peripheral
blood leukocytes of healthy donors. Use of pooled
lymphocyte DNA in representational difference
analysis opens the possibility for examining rare
banked tissues for which healthy control tissues
are not available. A 341-bp representational dif-
ference analysis band was isolated from MS tissues
with near sequence identity to a region of the ma-
jor DNA-binding protein gene of HHV-6 (44).
Detecting exogenous DNA in diseased tissue by
this technique, however, does not exclude the pos-
sibility that a commensal agent may be identified
that is not the cause of the disease being exam-
ined. HHV-6 is a neurotrophic virus present in
brain tissues from healthy control patients (51),
and more than (70%) of both MS patients and con-
trols were positive for the representational
difference analysis sequence by PCR (44). Although
case-patients and controls cannot be differenti-
ated by the presence or absence of these HHV-6
sequences, only MS tissues showed nuclear stain-
ing of oligodendrocytes surrounding plaques when
monoclonal antibodies against HHV-6 viral pro-
teins were used (44). There may be a subtle
difference in  tissue distribution for the virus in
MS patients not found in controls, or the HHV-6
variant B group 2 infecting MS plaques may be
particularly prone to generating the autoimmune
response seen in this disease.
GB Hepatitis Viruses
Since representational difference analysis relies
on PCR amplification, the technique is suited for
detecting agents with a DNA-based genome; se-
quences can be amplified by generating a cDNA
intermediate, but detecting RNA viruses is problem-
atic since mRNA expression patterns differ between
tissues and are likely to give spurious representa-
tional difference analysis bands. Simons and
colleagues overcame this problem by passing an
agent associated with non-A, non-B (NANB) hepati-
tis through primates and using cell-free extracts of
primate plasma for representational difference analy-
sis and discovered two new human hepatitis viruses
(52, 53).
A novel form of NANB hepatitis was first identi-
fied in a physician who became ill with hepatitis,
and the disease was transmitted to primates by in-
jecting serum from patients into the animals (54).
Extensive studies demonstrated that the virus,
named the GB agent, was different from all known
human hepatitis viruses (hepatitis A [HAV], hepati-
tis B [HBV], hepatitis C [HCV], and hepatitis E)
(55-57). Total RNA from the samples was reverse-
transcribed to obtain cDNA by using cell-free
preinfection and acute-phase plasma from infected
monkeys. After cDNA synthesis, representational
difference analysis was performed, and seven cDNA
clones were found to be specifically associated with
this form of hepatitis. Sequence analysis and com-
parison with other known hepatitis viruses
identified two unique flaviviruses, GBV-A and GBV-
B, as the GB agents (52, 53, 58). A third virus,
GBV-C, was subsequently identified using the
known GBV-A, GBV-B, and HVC consensus se-
quences (52b and see below).GBV-A and GBV-C
are closely related phylogenetically. Cross-chal-
lenge experiments showed that GBV-C probably
originated in human hepatitis patients, whereasVol. 2, No. 3—July-September 1996 Emerging Infectious Diseases
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GBV-A and B may be tamarin monkey viruses that
were inadvertently passaged along with the hu-
man virus (53, 58).
In addition to having difficulty in identifying
RNA viruses, representational difference analy-
sis has several other limitations. Polymorphic
human DNA can be amplified through this tech-
nique (5), and not all bands generated by it belong
to the suspected agent. Representational differ-
ence analysis may produce DNA fragments from
an agent whose genome has not been sequenced
(e.g., most bacteria and fungi), and sequence ho-
mology searches may be unable to distinguish the
agent’s genomic DNA fragments from unsequenced
human DNA. Only normally sterile site tissues are
appropriate for this technique because normal flora
that differs between tissue sites could result in
spurious amplification. Finally, for viruses with
small genomes, multiple restriction digests may
be required to identify a unique restriction fragment
of the appropriate size that can be efficiently ampli-
fied. Although the technique has been successfully
used by several groups to identify polymorphic DNA,
the procedure is complex and not uniformly repro-
ducible.
Consensus  Sequence–Based  PCR
Consensus sequence PCR relies on the use of
highly conserved DNA sequences, such as riboso-
mal RNA (rRNA) gene sequences from known organisms, to
amplify DNA from related organisms not yet discovered (59).
This technique is simple and extremely successful in identifying
new human pathogens. Subunit rRNA genes evolve in a rela-
tively slow and uniform manner, which makes these sequences
extremely useful for establishing phylogenetic relationships (59).
By using conserved DNA sequences from bacterial 16S rRNA
genes, at least two new bacteria associated with human dis-
eases have been identified (60, 61), and PCR amplification of
conserved hantaviral capsid DNA sequences resulted in the
rapid identification of a new hantavirus associated with an out-
break of severe pulmonary disease (1).
Unlike using representational difference analysis, using
consensus sequences to amplify DNA requires knowledge of
the suspected agent’s phylogenetic relationship to other or-
ganisms. The technique generally should be used on normally
sterile site tissues if sequences from normal flora are also likely
to be amplified. Although the lack of broadly amplifiable con-
sensus primers limits use of this technique to prokaryotic and
eukaryotic pathogens, consensus sequences are to likely exist
among many of the classes of viruses that eventu-
ally could be used in screening panels of diseased
tissues when a viral cause is suspected.
Bartonella: Bacillary Angiomatosis and
Cat-Scratch Disease
Phylogenetic studies of bacteria have relied on
comparisons of highly conserved rRNA gene se-
quences present in prokaryotes (62). rRNA genes
are present in all living cells and contain regions
of highly conserved sequences with intervening
variable regions. Conserved sequences can be used
to amplify and sequence the intervening variable
regions by PCR. This technique was exploited by
Relman and colleagues to identify the bacillus associated with
bacillary angiomatosis (60).
Bacillary angiomatosis is an inflammatory vascular prolif-
erative process that affects the skin, lymph nodes, and visceral
organs of AIDS patients (63). Although bacilli can be identified
by Warthin-Starry staining of lesions (64, 65), the suspected
causal organism was resistant to cultivation by standard tech-
niques. Consensus oligonucleotide primers complementary to
the 16S rRNA genes of eubacteria were used to amplify 16S
rRNA gene fragments directly from tissue samples (60). Phy-
logenetic analysis of the amplified DNA sequence showed that
the organism belonged to the genus Rochalimaea (now re-
named Bartonella) (60). Bartonella organisms
were also cultured from bacillary angiomatosis le-
sions (66) and blood from bacteremic patients (67,
68), and serologic analyses have associated the or-
ganisms with cat-scratch disease (69). Current
evidence suggests that bacillary angiomatosis in
HIV-seropositive patients results from infection
with either B. quitana  or a newly described
Bartonella species, B. henselae (68, 70), whereas
cat-scratch disease is primarily caused by infec-
tion with B. henselae (71) (for
review, see [72]).
Whipple’s Disease
Consensus sequence PCR was also used to iden-
tify an organism associated with Whipple’s disease,
one of the most persistent mysteries in microbiol-
ogy (61). Whipple’s disease is a systemic illness, first
described in 1907, characterized by arthralgias, di-
arrhea, abdominal pain, and weight loss (73).
Rod-shaped bacilli were identified histologically in
Whipple’s disease lesions in the early 1960s (74),
but the suspected bacteria were not culturable by
standard techniques (73). The agent was found to
be a gram-positive actinomycete (Tropheryma
whippelii gen.nov.sp.nov.), unrelated to any char-Emerging Infectious Diseases Vol. 2, No. 3—July-September 1996
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acterized species when a bacterial 165 rRNA se-
quence was amplified and sequenced directly from
infected tissue (61, 75).
Hantavirus Pulmonary Syndrome
Consensus PCR primers have been successfully
used to identify and classify bacteria, and similar
techniques can be used to diagnose new viral agents.
In May 1993, an outbreak of unexplained acute res-
piratory illness with a high death rate occurred in
the southwestern United States (76). In the initial
phases of the investigation, the cause of the syn-
drome was not clearly known to be infectious. Serologic tests
quickly detected cross-reactive antibodies to
known   hantaviral antigens in the serum of pa-
tients; these results suggested that a previously
unrecognized hantavirus was the cause of the dis-
ease (77). PCR primers, based on consensus
sequences within the G2 protein coding region of
the M segment of the genomes of known
hantaviruses, were designed and used in nested
reverse-transcription PCR to amplify a short seg-
ment of the viral genome from diseased tissues
(1).
Sequence analysis of the PCR products showed
that the amplicon differed from the other known
hantaviral sequences by least 30%, and phyloge-
netic analysis demonstrated that the new virus is
most closely related to Prospect Hill hantavirus
(1), a zoonotic hantavirus endemic in North
America (78). Hantavirus antigens have been de-
tected in endothelial cells from patients (1, 79),
and virus particles have been identified in infected
pulmonary endothelial cells and macrophages (80).
Deer mice (Peromyscus maniculatus) are the pri-
mary host for the virus (1), and the virus has been
passaged through laboratory-bred deer mice and
cultured in Vero E6 cells (2). This newly recog-
nized virus was originally named Muerto Canyon
virus (2) but has since been renamed Sin Nombre
virus in light of nomenclatural disputes regarding
the appropriateness of a descriptive name.
Complementary cDNA Library Screening
Identification of HCV and HGV
A third major approach to new organism identi-
fication relies on screening cDNA libraries made  from
diseased tissues by using hyperimmune serum from
specimens. This method was successfully used to
identify the cause of most cases of NANB hepatitis,
HCV. When serologic tests for HAV and HBV be-
came available, it became clear that most cases of
transfusion-associated hepatitis in the United States
were not caused by either virus (81, 82). Conven-
tional techniques failed to identify the agent responsible for most
cases of NANB hepatitis (83), despite evidence that the dis-
ease was caused by a bloodborne, small, enveloped virus readily
transmissible to chimpanzees (84, 85).
Since the virus was presumed to be an RNA virus, Choo
and colleagues made a cDNA expression library from RNA
isolated from an infected chimpanzee’s plasma (86). While the
GBV-A, B, C were identified by direct detection of viral cDNA
through representational difference analysis, HCV cDNA was
identified by immunologic detection of cDNA that was encod-
ing viral protein. Viral antigens expressed from
the cDNA library were identified by
immunoscreening with convalescent-phase human
sera. A cDNA clone was isolated encoding an anti-
gen that could be used to screen
convalescent-phase sera from patients with NANB
hepatitis. Identification of the clone rapidly led to
the production of a recombinant antigen used for
serologic screening to detect specific antibodies
in infected chimpanzees and patients with hepati-
tis after transfusion. Extended sequence analysis
demonstrated that the agent, now known as HCV,
is closely related to the family Flaviviridae and is
the major cause of NANB hepatitis throughout
the world (86, 87). Recently, the same approach
was successfully used to identify HGV, which has
been found to be almost identical to GBV-C, the
human hepatitis virus identified by representa-
tional difference analysis (88). The potential role
of HGV and GBV-C in human disease still remains
uncertain (88b).
Using convalescent-phase sera to screen cDNA
libraries from diseased tissues is a novel method
for pathogen identification. It is a potentially use-
ful technique for diseases in which well-defined
convalescent-phase sera are available, and it re-
quires tissues with a high titers of the agent. On
the other hand, constructing and screening DNA
libraries are laborious, and cross-reactive antigens
are likely to be detected, especially for diseases in
which autoantibodies are common.
Future Directions
Nucleic acid database information is rapidly ex-
panding for all classes of organisms, and a significant fraction of
the human genome has already been sequenced. Even small
laboratories can exploit new and relatively inexpensive mo-
lecular biologic technologies to search for new pathogens. Once
a small, unique nucleic acid fragment from a pathogen has been
identified, nucleic acid detection and serologic assays can often
be rapidly developed to establish an etiologic link with disease.
New pathogens are likely to be identified by some of these
molecular biologic approaches. A number of diseases have longVol. 2, No. 3—July-September 1996 Emerging Infectious Diseases
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been suspected to have an infectious cause and
are appropriate candidates for these techniques.
The eventual identification of infectious etiologic
agents of diseases such as sarcoidosis (89),
Kawasaki’s disease (90), and type I diabetes
mellitus is likely. New techniques, such as arbi-
trarily primed PCR and phage display libraries (91),
have not been used for pathogen discovery but
show promise for expanding the repertoire of tech-
niques available for identifying unculturable
agents. Three years passed between the initial
descriptions of AIDS and the identification of HIV
(92). Use of molecular biologic approaches could
lead to rapid identification and control of the next
pandemic caused by a newly emergent infectious
disease.
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